p53/p21 induction in an independent cohort. (A) The DNA-damage response (p53 basal levels, p21 induction) in all patients of the validation cohort. ○, 17p deletion; ■, sole TP53 mutation; •, no 17p deletion or TP53 mutation. (B) Top panel, Patients without the 11q deletion, the 17p deletion, or the TP53 mutation (n = 38) compared with patients with the 11q deletion (n = 18). Similar to the observation in the initial cohort, based on the cutoff, 8 samples (44%) with the 11q deletion showed a type-B defect. In the cohort without the 11q deletion, 17p deletion, or TP53 mutation, 5 cases (13%) showed a type-B defect. Bottom panel, Impaired p53 and p21 induction in patients with the 11q deletion was confirmed in the validation cohort (median induction of samples without the 17p deletion, 11q deletion, or TP53 mutation: 196.9; median of samples with the 11q deletion: 170.5; P = .0505).